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Abstract
Background—Asthma is a known risk factor for acute ozone-associated respiratory disease. Ozone
(O3) causes an immediate decrease in lung function and increased airway inflammation. The role of
atopy and asthma in modulation of O3-induced inflammation has not been determined.
Objective—To determine if atopic status modulates O3 response phenotypes in humans.
Methods—Fifty volunteers (25 normal volunteers, 14 atopic non-asthmatics, 11 atopic asthmatics
not requiring maintenance therapy) underwent a 0.4 ppm O3 exposure protocol. Ozone response was
determined by changes in lung function and induced sputum composition, including airway
inflammatory cell concentration, cell surface markers, cytokine and hyaluronic acid concentration.
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Results—All cohorts experienced similar decreases in lung function post O3. Atopics and atopic
asthmatics had increased sputum neutrophils and IL-8 after O3 exposure; levels did not significantly
change in normal volunteers. Following O3 exposure, atopic asthmatics had significantly increased
sputum IL-6 and IL-1 β, and airway macrophage TLR4, FceRI, and CD23 expression; levels in
normal volunteers and atopic non-asthmatics showed no significant change. Atopic asthmatics had
significantly decreased IL-10 at baseline compared to normal volunteers: IL-10 did not significantly
change in any group with O3. All groups had similar levels of hyaluronic acid at baseline, with
increased levels after O3 exposure in atopics and atopic asthmatics.
Conclusion—Atopic asthmatics have increased airway inflammatory responses to O3. Elevated
TLR4 expression suggests a potential pathway through which O3 generates the inflammatory
response in allergic asthmatics but not in atopics without asthma.
Clinical Implications—These observations suggest that mild atopic asthma confers increased risk
for exacerbation of O3-induced lung disease through promoting an enhanced innate immune
inflammatory response to O3.
Keywords
ozone; innate immunity; asthma; atopy; hyaluronic acid; environmental airways disease;
interleukin-1 beta; interleukin-10
Introduction
Ozone (O3) is a commonly encountered environmental pollutant. Asthma morbidity (ER visits,
hospitalizations, rescue medication use) is clearly associated with exposure to increased levels
of ambient air O3 1 Asthmatics are thought to have increased susceptibility to O3 due to
aggravation of underlying allergic airways inflammation. Ozone exposure studies have shown
that O3 induces an airway granulocyte response, characterized by sputum neutrophilia in
healthy volunteers 1–3 and sputum neutrophilia and eosinophilia in atopic asthmatics 4. Ozone
challenge has also been found to enhance responses to subsequent inhaled allergen challenge
in mild atopic asthmatics 5–7. The ability of O3 to enhance airway inflammation and enhance
responsiveness to subsequent inhaled allergen likely play important roles in asthma
exacerbation. However, it is unclear if non-asthmatic persons with atopy also have enhanced
susceptibility to O3 as has been shown in atopic asthmatics. Khatri and colleagues found
associations between air quality and airway inflammation in both asthmatics and non-
asthmatics with allergies 8, suggesting that atopic status itself may contribute to O3-induced
inflammatory response in the airway.
Our group has also observed that response to inhaled lipopolysaccharide (LPS) yields airway
inflammatory responses similar to those seen after O3 exposure. Like O3 exposure, airway LPS
challenge induces airway neutrophilia, enhances response to inhaled allergen in allergic
subjects 9–11, and induces airway pro-inflammatory cytokines1. We and others have also found
that O3 and LPS induce selective increases in specific macrophage and monocyte populations
in the airway 12 and that O3 induces influx of monocytes and macrophages with increased
expression of CD11b and CD14, 13a co-receptor for LPS. Building on these observations, our
group has recently found correlations in airway inflammatory responses in healthy individuals
who underwent both O3 and LPS exposures (Hernandez, in press). The similarities between
responses of normal volunteers and atopic asthmatics to O3 and LPS suggest that atopy
modifies response to a number of innate stimuli and that common molecular mechanisms
account for response to both O3 and LPS.
Consistent with this idea, mechanistic studies in mice suggest that at least some O3 responses
are mediated through the primary LPs receptor, TLR4 14–16. As O3 is a reactive oxygen
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molecule, it is unlikely that a discrete receptor exists which modulates response to this agent,
or that O3 would act directly on airway monocytes or macrophages to induce airway
inflammation. Indeed, in vitro studies of airway macrophages or THP-1 cells exposed to O3
do not reveal an O3-induced release of inflammatory mediators 17–19. It seems more likely that
O3 exerts a biological effect via interaction with components of airway lining fluid to produce
secondary signaling molecules or danger signals which cause inflammatory responses. Ozone
challenge of airway epithelial cells in culture has been shown to result in NF-κB activation and
production of a variety of mediators 20–22. Pro-inflammatory mediators such as IL-8 are among
those associated with O3-induced inflammation in asthmatics 23 and reduced levels of the anti-
inflammatory cytokine IL-10 have been reported in asthmatics at baseline 23–25. Hyaluronic
acid (HA) is an endogenous pro-inflammatory ligand for CD44 and TLR4 26–28 and may be
an important mediator in asthma. Hyaluronic acid has also been recently identified as a
candidate host danger signal which mediates O3-induced inflammatory responses 29, 30.
At present, it is unclear if O3 modifies levels of TLR4 in humans, and if atopic status itself
modifies the O3-induced airway inflammatory response. The present study tests the hypothesis
that atopic status alone modifies lower airway inflammatory response to a 0.4 ppm O3 exposure
through examination of airway inflammatory cells and airway epithelial cell lining fluid from
induced sputum.
Methods
Volunteer Recruitment and Inclusion Criteria
These protocols were reviewed and approved by the University of North Carolina Committee
on the Rights of Human Subjects (Institutional Review Board). All subjects underwent a
physical examination, routine blood panel with CBC and differential cell count, allergy skin
testing, and methacholine challenge. Atopy was demonstrated by positive immediate skin test
response to one of the following allergen mixes: two species of house dust mite
(Dermatophagoides farinae and Dermatophagoides Pteronyssinus), cockroach, tree mix, grass
mix, weed mix, mold mix 1, mold mix 2, rat, mouse, guinea pig, rabbit, cat or dog. A positive
methacholine challenge was determined as having a drop of 20% from post-saline FEV1 at a
level of 10 mg/ml or less of methacholine. This study was an analysis of lung function data
and samples obtained from a total of 50 subjects that were stratified into three groups based
on the results of their allergy skin testing and methacholine challenge. Allergic asthmatics (AA,
N=11) had positive skin prick testing and positive methacholine challenge and were required
to have mild intermittent asthma, as defined by National Heart, Lung, and Blood Institute
(NHLBI) 2007 guidelines (not on inhaled corticosteroid or leukotriene receptor antagonist
therapy). Normal volunteers (NV, N=25) had negative skin prick testing and negative
methacholine challenge, and atopic volunteers (N=14) had positive skin prick testing and
negative methacholine challenge. All AA volunteers were newly recruited into this study
protocol while other subjects were derived from previously completed studies 12, 31. Female
subjects had to have a negative urine pregnancy test prior to challenge and all volunteers were
required to be free of chronic cardiovascular illness, and be free of acute respiratory illness
within 4 weeks of O3 challenge. All subjects had FEV1 and FVC ≥ 80% predicted normal for
height and age 32, and FEV1/FVC ≥ 0.75 and were non-smokers with no smoking history. All
subjects were screened for their ability to provide an adequate induced-sputum sample during
their training session. Subjects provided an induced sputum sample during the screening visit
and at 4–6 h after the O3 exposure. Sputum induction and processing methods are found in the
online repository.
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Spirometry testing was preformed according to ATS/ERS recommendations using the Viasys
VMax 229 series spirometers. All subjects were seated, and at least 3 maneuvers were obtained,
with the best of the three reported.
O3 Exposure protocol
O3 Inhalation Challenge: The O3 exposures were conducted in an O3 exposure chamber at the
US-EPA Human Studies Facility on the campus of the University of North Carolina, Chapel
Hill, NC. Each subject was exposed to O3 (0.4 ppm) for 2 hours while performing four 15
minute sessions of intermittent moderate exercise (minute ventilation or VEmin = 30–40 L/
min) on a treadmill, separated by 15 minutes of seated rest. Spirometry, breath sounds, and
vital signs were assessed before and immediately after exposure. Sputum was obtained 4–6
hours post exposure and processed as previously described 12, 31, 33, 34. Sputum was assessed
for total and differential cell counts, flow cytometric assessment of CD11b, CD14, CD86,
TLR4, FceRI, CD23, and HLA-DR on macrophages and monocytes 12, 35. Sputum
supernatants were also assessed for cytokine concentration.
Flow cytometry
Expression of selected cell surface molecules on sputum leukocytes was quantified via
multicolor flow cytometry (FCM) using a BD LSR-II flow cytometer (BD Immunocytometry
Systems; San Jose, CA). These included molecules associated with antigen presentation and
specific immunity (CD86/B7.2, HLA-DR/MHC-II,), as well as innate immune function
(CD11b/CR3, CD14/LPS receptor). First, sputum leukocytes were differentiated from cellular
debris, bacteria, yeast, squamous and bronchial epithelial cells by gating on CD45 (pan
leukocyte marker) positive cells. Up-or down-regulation of specific surface molecules was
quantified as a change in the mean fluorescent intensity (MFI) of the gated population.
Fluorochrome-labeled antibodies were obtained from BD Biosciences (CD11b-PE-CY5,
CD45-APC-Cy7, HLA-DR-PerCP, Beckman-Coulter (CD14-APC, CD86-PE). Appropriate,
nonspecific, labeled isotypic control antibodies were also obtained from these sources.
Mediator Measurement
Cytokines from sputum supernatants were measured using multi-plex technology Meso
ScaleDiscovery/MSD, Gaithersburg, MD). Each sample was analyzed with the HumanMIP-1
alpha Ultra Sensitive Kit (LOT#: K0031370) and the Human TH1/TH2 10-Plex Ultra Sensitive
Kit (LOT#: K0031431). All supernatant samples were diluted 1:4 and had a final DTT
concentration of < 1mM where no deleterious effects have been observed using the MSD
platform.
Hyaluronic Acid Measurement
Hyaluronic acid (HA) levels from induced sputum supernatants were performed with a
commercially available enzyme-linked immunosorbent assay (Echelon, San Jose, CA) with
minor modifications. The lowest concentration of available standard was 50 ng/ml. This was
diluted 1:1 to make a 25 ng/ml standard, and the 25 ng/ml standard was diluted 1:1 to make a
12.5 ng/ml standard. In addition, standards were run with and without 0.1% DTT without
notable differences in standard concentrations. Concentrations of HA from sputum
supernatants were compared to standards containing DTT. The standard curve generated was
log linear from 12.5 ng/ml to 1600 ng/ml.
Hernandez et al. Page 4














The primary hypothesis to be tested was that atopic asthmatics or atopic non-asthmatics had
increased susceptibility to ozone compared to normal volunteers, with the primary endpoint
being sputum neutrophils. Changes in cell counts/mg sputum, differential cell count percentage
(sputum), mean fluorescence intensity (MFI) measures (flow cytometry), cytokine values, and
HA levels pre- and post-O3 exposures within each cohort were assessed. To determine if a
particular cohort responded to O3, non-parametric paired Wilcoxon signed rank test was
employed. Differences between either atopic asthmatics or atopic non-asthmatics and normal
volunteers were analyzed using non-parametric t tests (Mann-Whitney Test). To confirm that
baseline values between all three groups were not different, non-parametric one way analysis
of variance (Kruskall Wallis Test) was employed. Significance was set at a p= 0.05.
Results
Demographics
Demographic data for the 50 volunteers, ranging in age from 19 to 39 years, recruited for
challenge to 0.4 ppm of O3 are presented in Table 1. Fourteen were atopic, though they could
not exhibit symptoms of atopy at the time of exposure. Eleven were atopic asthmatics, none
of whom were on maintenance inhaled corticosteroid therapy or other scheduled drug.
Effect of 0.4 ppm Ozone on Lung Function
The effect of O3 on lung function in cohorts of normal volunteers (n=25), atopics (n=13), and
atopic asthmatics (n=11) was compared. Ozone caused similar significant decreases in mean
FEV1 (p<0.001 all cohorts) and FVC (p<0.001 normal volunteers, p=0.003 atopics and atopic
asthmatics) immediately after challenge in all cohorts (Figure 1) compared to their baseline
values.
Effect of 0.4 ppm Ozone on Airway Leukocyte Numbers
The effect of O3 on airway neutrophil, macrophage, and eosinophil numbers was a primary
endpoint for this study. Paired data (pre and post O3 exposure) was available for 25 normal
volunteers, 13 atopics, and 10 atopic asthmatics. Figure 2A shows that the atopic and the atopic
asthmatic cohorts had significantly increased sputum neutrophil numbers (cells/mg sputum,
p=0.045 atopics, p=0.04 atopic asthmatics) 4 hours after challenge. Although sputum
neutrophils increased in normal volunteers, the increase in mean neutrophil numbers did not
reach statistical significance, which may have been influenced by more variable baseline
neutrophil numbers. Although macrophage numbers (cells/mg sputum) (Figure 2B) decreased
in all cohorts, this was significant only among the atopic asthmatic volunteers (p=0.01). Figure
2C shows that eosinophil numbers at baseline were elevated in the airways of atopic (p=0.0002)
and atopic asthmatic volunteers (p=0.0002) compared to very low values in normal volunteers.
After O3 exposure, eosinophil numbers did not significantly change in the atopics or the atopic
asthmatics and remained very low in normal volunteers.
Changes in Airway Cytokines following Ozone
We also examined sputum supernatants for a number of immunoregulatory cytokines (IL-1β,
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, macrophage inflammatory protein 1 alpha,
TNF alpha and Interferon gamma). Sputum supernatants were available for 24 normal
volunteers, 12 atopics, and 10 atopic asthmatics. Four cytokines (IL-1β, IL-8, IL-6, and IL-5)
were significantly altered by O3 exposure and this occurred only in the atopic and atopic
asthmatic cohorts. Atopic asthmatics had significant increases in IL-1β (p=0.03), IL-8
(p=0.01), and IL-6 (p=0.01) (Figures 3A–C), while atopics had increased IL-8 (p=0.02) (Figure
3B) and IL-5 (p=0.03) following O3 exposure (data not shown). Two atopic asthmatic subjects
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had higher baseline and post O3 levels of IL- β and IL-8 compared to the rest of the cohort.
Analysis of the data excluding these two subjects showed that the change in IL-8 and IL-β was
significant (p=0.04) and close to significant (p=0.08) for these cytokines, respectively. We
further analyzed the IL-1β data as % change from baseline; using this metric we found a
significant difference when comparing NV vs. AA (p=0.009) (data not shown). When
comparing baseline values, atopic asthmatics had increased IL-1β compared to normal
volunteers (p=0.02) or atopics (p=0.05) (Figure 3A). No group experienced significant
increases in IL-10 after O3 exposure. However, atopic asthmatics had significantly decreased
IL-10 at baseline compared to normal volunteers (p=0.007) (Figure 3D).
Change in Sputum Hyaluronic Acid after Ozone Exposure
Pre and post O3 exposure sputum supernatant samples from 10 subjects in each cohort were
available for analysis. There were no differences in HA levels at baseline or after O3 exposure
among the cohorts (Figure 3E). Ozone exposure caused increased HA levels in atopics
(p=0.004) and atopic asthmatics (p=0.002) compared to their respective baseline values.
Changes in Cell Surface Markers following Ozone
Macrophages from induced sputum were isolated as discussed in the methods, and changes in
cell surface markers are presented in Figure 4 (n=13 normal volunteers, 7 atopics, and 6 atopic
asthmatics). Macrophages in the atopic asthmatic cohort had increased expression of CD23
(p=0.003), FceRI (p=0.03), and TLR4 (p=0.03) after O3 exposure (Figure 4A–C). All cohorts
showed increased CD11b after O3, but this increase attained significance only in the atopic
(p=0.02) and atopic asthmatic (p=0.03) cohort (Figure 4D). There were no other significant
changes in cell surface markers (CD80, CD86, TLR2, CD14, and HLA-DR) following O3 in
any cohort (data not shown).
Discussion
There are numerous epidemiologic studies linking increased environmental O3 levels with
asthma exacerbations. Asthmatic susceptibility to ambient O3 has been purported to be due to
enhanced underlying allergic airways inflammation 4, 36, however, not all studies have
observed modified allergic airways inflammation following exposure in atopic individuals 4,
37.
In this study we examined whether atopic status alone or mild intermittent atopic asthma
influenced the airways inflammatory response to inhaled O3. We found that all cohorts
experienced similar decreases in lung function (FEV1 and FVC) immediately after O3
exposure, with no difference among cohorts. Atopy or atopic asthma did not appear to influence
this immediate effect on lung function thought to be a reflex-mediated phenomenon triggered
in part by eicosanoids 38, 39. We did find that although all cohorts had increased sputum
neutrophils compared to their baselines after O3 exposure, these differences were significant
only in atopic and atopic asthmatic subjects. We note however that the atopic and atopic
asthmatic cohorts had less variability in their baseline PMNs/mg than the normal volunteers.
We can speculate that atopic status may have influenced the variability of baseline neutrophilia
when compared to normal volunteers. The potent neutrophil chemoattractant IL-8 was
significantly increased only in the atopic and atopic asthmatic cohorts following O3 exposure
with no significant differences between them. Thus, some markers of neutrophilia appear to
be influenced by atopic status at the early time point sampled. However, the present study is
limited in that we cannot comment on more chronic inflammatory changes such as reduced
lung function or sputum neutrophilia that may selectively persist in some cohorts 24 hours after
O3 exposure, t he time frame with which O3-induced asthma exacerbations are associated.
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Although 0.4 ppm O3 did not significantly increase sputum eosinophils in this mild asthmatic
cohort, we did find that O3 exposure upregulated cell surface expression of FceRI and CD23,
the high and low affinity IgE receptors respectively, in the macrophages of atopic asthmatics.
This finding suggests that O3-induced airway macrophages from atopic asthmatics have
enhanced the ability to participate in the antigen uptake process40 following O3 exposure. In
the past our group has shown that macrophages of allergic asthmatics have enhanced particle
uptake capability compared to normal volunteers 35.
The lack of change in sputum eosinophils may be influenced in great part by the timepoint
sampled (4 hours post O3), as previous studies by our group showed increased eosionphils in
atopic asthmatics 18 hours post exposure 4. Of notable interest were the elevated baseline
sputum eosinophils in the atopic non-asthmatic and the atopic asthmatic cohorts. This
observation has been documented by two other groups 41, 42 in bronchial biopsy specimens,
where baseline numbers appear to reflect atopic status alone. What is unclear is if and how
these elevated baseline eosinophil numbers influence eosinophil trafficking at later timepoints
and/or eosinophil activation with consequent exacerbation of disease.
In addition to O3’s enhancing allergic airways inflammation, we found that mild atopic
asthmatics had increased cell surface expression of TLR4 on mature macrophages after O3
exposure. This finding corroborates murine studies of O3 challenge, where O3 exposure alone
has been shown to upregulate TLR4 on murine alveolar macrophages 43. Mechanistic studies
in animals suggest that at least some responses to O3 are mediated through TLR4 and
consequent elaboration of innate immune cytokines such as IL-1 β 30. Hollingsworth and
colleagues have showed that compared to wild type mice, TLR4 deficient mice had reduced
airway hyper-responsiveness following subacute O3 exposure 15, and that inflammatory
cytokine expression was altered in a TLR4 dependent manner 30. The role of TLR4 in O3-
induced inflammation is further highlighted by our HA observations. Hyaluronan has recently
been identified as an endogenous ligand of TLR426–28 and has been found to mediate O3-
induced airway hyper-responsiveness29, 30 and pro-inflammatory cytokine production.30 Our
finding of significantly increased HA levels in atopic and atopic asthmatic subjects but not in
normals, makes the HA-TLR4 link an interesting mechanism to explore in future O3 studies.
We hypothesize that atopic asthmatics expressed more surface TLR4 on airway macrophages
due to a combination of factors: a). increased potential ligands stimulating increased TLR4
expression, and/or b). the baseline cytokine environment in the atopic asthmatic cohort with
increased IL-1β and decreased IL-10. Our HA assay was limited in that we could not distinguish
between low and high molecular weight forms; the low molecular weight form serving as a
putative TLR4 ligand. Atopic asthmatics may have had increased endogenous TLR4 ligands
that were not assayed for in the present study. The baseline cytokine environment may also
influence susceptibility to augmenting TLR4 expression, as others have shown that IL-10 can
downregulate TLR4 expression 44, and that IL-1β overexpression is capable of provoking the
release of endogenous TLR4 ligands 45, enabling TLR4-mediated production of cytokines such
as IL-1β, IL-6, and IL-8.
In addition to the elevated IL-1β at baseline in the atopic asthmatic cohort, we found that
IL-1β and IL-6 were elevated after O3 exposure in atopic asthmatics. This suggests an important
role for IL-1β and possibly activation of the NLRP3 inflammasome which is central in release
of IL-1β from macrophages. Administration of (human) IL-1 receptor antagonist before and
after O3 exposure has been shown to prevent the development of airway hyper responsiveness
and blunt increases in pro-inflammatory cytokines, as well as decrease neutrophilia in
bronchoalveolar lavage (BAL) fluid in a mouse model of O3-induced lung injury 46. Similar
to our study, IL-1β levels have been reported to be greater in BAL fluid and sputum of
asthmatics compared to normal volunteers47, with airway macrophages from asthmatics also
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having increased expression of IL-1β48. Most notably, IL-1β has been shown to be elevated in
BAL fluid from persons with symptomatic asthma vs. those with asymptomatic asthma 49. Our
findings highlight the heterogeneity of IL-1β values at baseline and following O3 exposure in
very mild asthmatics. Interestingly, Hastie et al. recently analyzed induced sputum from
asthmatics stratified by granulocyte populations and found that those asthmatics who had >40%
sputum neutrophils, independent of eosinophil level, had increased IL-1β compared to sputa
with <40% neutrophils50. It is plausible then that in asthmatics with neutrophil-driven
inflammatory responses, such as those evoked by O3 exposure or endotoxin inhalation
challenge, IL-1β may play a significant role in the disease state. However, the importance of
IL-1β in response to O3 exposure will need to be confirmed in a follow up study with a larger
sample size. We hypothesize the increased TLR4 expression correlates with increased pro-
inflammatory cytokine production, as has been shown in TLR4 transgenic animals 51. Taken
together, our data on TLR4 and IL-1β lead us to suggest that innate immune inflammatory
pathways involving activation of TLR4 and subsequent release of IL-1β may play an important
role in driving O3-induced asthma exacerbations. Release of an endogenous TLR4 ligand may
activate the NLRP3 inflammasome, with consequent production and release of IL-1β,
documented in other models of sterile inflammation 52.
Another possible explanation for increased inflammatory cytokine production and increased
TLR4 and IgE receptor surface expression after O3 exposure in atopic asthmatics may be the
decreased level of IL-10 at baseline, with no increase after O3 exposure. Interleukin-10 is a
potent anti-inflammatory cytokine, suppressing the production of a multitude of pro-
inflammatory cytokines by activated macrophages, such as TNF-α, IL-β, IL-6, macrophage
inflammatory protein-α, and IL-853. Decreased levels of IL-10 have been reported in the
BAL24 and induced sputum25 of asthmatics compared to non-asthmatics. In the present study
we found that baseline IL-10 levels in sputum of allergic asthmatics were significantly
decreased compared to normal volunteers (p=0.007), and there was a similar trend for
difference with atopic non-asthmatics (p=0.09). Studies of IL-10 knockout mice indicate that
IL-10 appears to be protective against O3-induced neutrophilic inflammation and NFkB
activation54. Therefore, suppressed baseline IL-10 in our atopic asthmatic cohort may have
contributed to increased pro-inflammatory cytokine production after O3 exposure.
In conclusion, we report that atopic asthmatics exposed to O3 exhibit an elevated response of
pro-inflammatory cytokines (IL-1β, IL-6, IL-8), TLR4 and IgE receptor expression in the
airways. We suggest this airways milieu may confer increased reactivity to subsequently
inhaled allergen and innate immune ligands. Low levels of IL-10 in the airways of atopic
asthmatics may underlie this reactivity to O3. We propose that these findings have important
health implications, as clarifying the mechanisms underlying susceptibility to
environmentally-induced asthma and modulators of these inflammatory pathways, such as
microRNAs 55 may allow for the development of more targeted traditional or alternative
therapies to prevent asthma exacerbations.
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Baseline and post O3 exposure FEV1 (A) and FVC (B). n=25 normal volunteers (NV), 13
atopics, and 11 atopic asthmatics (AA). Data bars depict mean and standard error of the mean.
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Changes in inflammatory cell infiltrate in sputum (cells/mg sputum) in response to O3. N=25
normal volunteers, 13 atopics, and 10 AA. Lines depict mean and standard error of the mean.
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Changes in induced sputum cytokines and hyaluronic acid (HA) in response to O3. N=24 NV,
12 atopics, and 10 AA for sputum cytokines, N=10 each cohort for HA measurement in sputum.
Lines depict mean and standard error of the mean.
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Changes in cell surface marker expression (MFI) on induced sputum macrophages. N=13
normal volunteers (NV), 7 atopics, and 6 atopic asthmatics. Lines depict mean and standard
error of the mean.
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Table I
Study Demographics
Cohort No. Age (y) Gender Race
Normal Volunteer 25 23.7 ± 3.8 14 F / 11 M 19 white, 5 African American, 1 Asian
Atopic 14 25.2 ± 5 7 F / 7 M 8 white, 5 African American, 1 Asian
Atopic Asthmatic 11 26.3 ± 6.5 6 F / 5 M 8 white, 3 African American
*
Atopy was determined by a positive skin prick test response to a panel of environmental allergens. Asthma status was determined by means of
methacholine challenge.
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